Over 2,000 US Physicians Surveyed by M3 Global Research Reveal Some Surprising Insights
(Washington, DC, September 10th, 2013)- MDLinx (www.mdlinx.com), a part of M3 Group, is slated to present new data from its CompleteSpecialist series of syndicated market research on Monday, September 16th, at the annual ePharma Summit West in San Francisco. The detailed syndicated market research study explores how physician specialists communicate with each of their practice audiences: patients, peers, payers and pharmaceutical companies. The report also details and the respective value and influence specialists ascribe to each type of channel. It is the only study of its kind to date, and it breaks new ground in understanding communication and promotion to the specialties that it covers.
“The differences and diversity among specialty physicians’ preferences continue to demand current, in depth research and understanding,” comments Jack Bilson, VP of Product Development & Innovation for M3 Group. “One eye opening insight revealed from the research showed that the satisfaction of several specialist physicians with self-directed edetails was among the most preferred of all promotional tactics even in comparison to Medical Science Liaison interactions.” At the conference, Mr. Bilson will share more key findings and analysis in his presentation, Promotional Preferences among Specialty Physicians in the U.S.
“In leveraging the valued insights from multiple sources within the M3 Group we have uncovered some new perspectives. This new data both reinforces and at times challenges conventional wisdom about the communication behavior and habits of physicians,” says Bilson.
About M3 Group
The M3 Group operates in the US, Asia, and Europe with over 1.2 million physician members globally via its physician websites such as www.m3.com, www.mdlinx.com, www.doctors.net.uk, and www.medigate.net. MDLinx is an award-winning, practical medical information tool used by busy physicians and healthcare professionals to stay up to date with the latest research in the medical field. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (jp:2413) with subsidiaries in major markets including USA, UK, Japan, S. Korea, and China. M3 Group provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices in Tokyo, Washington D.C., Fort Washington, PA, Oxford, London, and Seoul.